Signalling by Hh (Hedgehog) proteins is among the most actively studied receptor-mediated phenomena relevant to development and post-embryonic homoeostatic events. The impact of signalling by the Hh proteins is profound, and work pertaining to the presentation of these proteins and the pathways engaged by them continues to yield unique insights into basic aspects of morphogenic signalling. We review here the mechanisms of signalling relevant to the actions of Hh proteins in vertebrates. We emphasize findings within the past several years on the recognition of, in particular, Sonic hedgehog by target cells, pathways of transduction employed by the seven-pass transmembrane protein Smoothened and end points of action, as manifest in the regulation of the Gli transcription factors. Topics of extended interest are those regarding the employment of heterotrimeric G-proteins and G-protein-coupled receptor kinases by Smoothened. We also address the pathways, insofar as known, linking Smoothened to the expression and stability of Gli1, Gli2 and Gli3. The mechanisms by which Hh proteins signal have few, if any, parallels. It is becoming clear in vertebrates, however, that several facets of signalling are shared in common with other venues of signalling. The challenge in understanding both the actions of Hh proteins and the overlapping forms of regulation will be in understanding, in molecular terms, both common and divergent signalling events.
INTRODUCTION
The Hh (Hedgehog; referring to the protein in Drosophila or the Hedgehog proteins collectively in vertebrates) family of secreted proteins has generated considerable interest in the past decade, as the proteins are recognized to serve in an ever-widening array of biological events and employ unusual, if not sometimes unique, modes of signalling. Of considerable importance are the roles of this family in a variety of developmental phenomena [1] [2] [3] [4] . The most actively studied of these in vertebrates is the induction of ventral cell fates in the CNS (central nervous system) and the patterning of the anterior-posterior axis of the developing limb. Developmental roles are also played in vasculogenesis/angiogenesis, bone and cartilage formation, and lung branching morphogenesis. Also of interest are the homoeostatic functions of the Hh family in post-embryonic tissues, for example the maintenance of certain stem cell populations [5] [6] [7] [8] [9] [10] [11] . Deficits in one or more components of Hh signalling translate into developmental defects [12, 13] , and unrepressed signalling underlies several cancers [14, 15] .
The mechanisms by which Hh proteins are synthesized and presented to target cells, the means by which recognition of these proteins is achieved, the identities of pathways subsequently engaged by the proteins and the derangements that can occur at any level are all, for obvious reasons, areas of active investigation. In the present review, we will focus on those events specifically relevant to transduction of the Hh signal from the recognition of Hh proteins to the regulation of the Gli family of transcription factors in vertebrate cells. A great deal of progress has been made in this area, supporting the notion that several key events diverge from those defined in Drosophila and that some of these events overlap with those commonly engaged by other signalling molecules. However, much remains to be resolved. The question of what actually defines the most proximal response to the Hh proteins represents the greatest challenge.
OVERVIEW OF Hh SIGNALLING
The Hh family of proteins in mammals comprises Shh (Sonic hedgehog), Ihh (Indian hedgehog) and Dhh (Desert hedgehog). Shh is the most widely expressed and the most actively investigated. When synthesized Shh gains entry to the secretory pathway and undergoes the same forms of processing as Hh in Drosophila, i.e. endoproteolysis to yield N-Shh (cholesterol-modified Nterminal fragment of Shh; approx. 19 kDa for Shh; see Mann and Beachy [16] for a detailed review of processing). N-Shh is subsequently palmitoylated at the N-terminal cysteine residue. One or both lipid modifications are involved in the targeting of N-Shh to lipid rafts [17] , multimerization of N-Shh [17, 18] , establishment of morphogenic gradients [17, 19, 20] and potency at the target cell, [21] ; closely tied with the maturation and release of N-Shh are the actions of the protein Dispatched A [22, 23] . Once secreted, N-Shh exerts most, if not all, of its actions on target cells through Ptch1 (Patched1; Figure 1 ). Ptch1 is a 12-pass TM (transmembrane) protein that, in the absence of N-Shh, represses the activity of a seven-pass TM protein, Smo (Smoothened). Binding of N-Shh to Ptch1 inhibits repression of Smo, leading to activation of some genes and de-repression of others through the effects of Smo on the Gli family of transcription factors. Several excellent reviews compare the production of, and response to, Hedgehog proteins in Drosophila and vertebrates [24] [25] [26] [27] .
Models used in the analysis of N-Shh signalling range from gene activation in homogeneous populations of cells in monolayer culture to developmental patterning in embryos. NIH 3T3 and C3H10T1/2 cells have the properties of targets, in that N-Shh can activate the Gli transcription factors of these cells through pathways involving endogenous Ptch1 and Smo. One of the most commonly employed assays for N-Shh activity in these cells utilizes a luciferase reporter gene selective for Gli [28] . HEK-293 (human embryonic kidney 293) cells are used occasionally in studies of proximal events relevant to overexpressed Smo [29] [30] [31] . In vivo assays for the actions of N-Shh almost always exploit patterning, principally dorsal-ventral specification of the neural tube and digit identity in the limbs, and use the expression of easily identified downstream genes as molecular outputs. Experimental interference with, or overexpression of, purported components of Hh protein pathways are routinely achieved in zebrafish and avian embryos [32] [33] [34] . A well-established ex vivo assay for N-Shh activity in the mouse embryo is the neural plate explant culture [35] [36] [37] . Assays that rely on pattern abnormalities, although highly sensitive to the manipulation of the N-Shh pathway, are inherently complex and not always N-Shh specific. A complete understanding of any pathway engaged by N-Shh will always require a reiterative approach capitalizing on the tractability of cells in culture and the allowance of physiological events. A complete understanding must also take into account the potential for differences in forms of signalling among different cells.
N-Shh RECEPTION
Ptch exists in vertebrates as two isoforms, Ptch1 and Ptch2, which seem to be equivalent in terms of binding the three Hh isoforms. The two proteins are 73 % similar, with the greatest divergence being in TM domains 6 and 7 [38] . Ptch2 is dispensable in embryonic development, but a deficiency in Ptch2, in conjunction with Ptch1 haplo-insufficiency, increases the incidence of several types of tumours [38] . Almost all the actions of N-Shh are exerted through Ptch1. The repression of Smo by Ptch1 appears to be of a catalytic nature, as one molecule of Ptch1 can inactivate approx. 250 molecules of Smo [39] . An alternative mechanism of repression, involving formation of a physical complex between Ptch1 and Smo, is supported by the immunoprecipitation of such complexes from cells [40] , but is made less attractive by the finding that, in Drosophila, Ptch and Smo exist mostly in different subcellular localizations by microscopy [41] . An interesting idea, applicable to both models, is that Ptch1 achieves the repression of Smo in some fashion through a channellike activity, possibly involving its sterol-sensing domain. Point mutations in conserved residues of this domain indeed abrogate Ptch1's inhibition of Smo in Drosophila [42, 43] . Repression of Smo by Ptch1 is not necessarily cell autonomous. When Ptch1-deficient C3H10T1/2 cells containing a Gli-responsive promoter driving expression of a luciferase reporter gene were mixed with cells expressing Ptch1, a trans-inhibition of the reporter was noted in the absence of cell fusion [44] . The inhibitory compound identified in the extracellular milieu of Ptch1-overexpressing cells was pro-vitamin D 3 , which upon isomerization to the vitamin inhibited Smo with an IC 50 in the micromolar range.
Signal initiation by N-Shh requires the formation of a ternary complex with Ptch1 and the protein BOC [Brother of CDO (CAMrelated/down-regulated by oncogenes)] or CDO (homologues of the Drosophila iHog) [45] [46] [47] . BOC and CDO belong to the Immunoglobulin superfamily of single-transmembrane proteins, and have been found in COS cells to contact N-Shh through their FN3 (fibronectin type III repeat) domain. RNAi (RNA interference) targeting BOC or CDO renders NIH 3T3 and C3H10T1/2 cells unresponsive to N-Shh stimulation. Animals lacking CDO show signs of impaired Shh signalling, with mild holoprosencephaly and a solitary middle incisor [45] .
Smo AS A GPCR (G-PROTEIN-COUPLED RECEPTOR)
The structure of Smo as a seven-pass TM protein supports the idea that Smo can couple to heterotrimeric (αβγ ) G-proteins; a property shared among a very large number of cell-surface sevenpass TM receptors for hormones, paracrine factors and sensory stimuli. Smo falls into the frizzled/taste 2 family of vertebrate seven-pass TM receptors, one of the five families defined by phylogenetic analysis [48] . A seven-pass TM receptor couples to G-proteins within one or a combination of the G s , G i , G q and G 12 families and, on assumption of an active conformation, effects through them changes in second messengers, activities of lipid and protein kinases and activities of monomeric G-proteins. A sevenpass TM structure does not, however, guarantee the capacity of a protein to couple to G-proteins, and G-proteins are not the sole means by which signal transduction through seven-pass TM receptors can occur. Whether Smo couples to G-proteins has in fact been controversial.
Certainly no evidence for the coupling of Smo to G-proteins has been obtained in Drosophila. Lum et al. [49] addressed the question directly, noting that the response to Hh of a Ptch promoterluciferase reporter gene in wing imaginal disc-derived cl-8 cells was unaffected by RNAi targeting individual or multiple G α and G β genes. Ingham and McMahon [2] , moreover, cite the absence of any report of a G-protein mutation that disrupts Hh signalling. The absence of a report of this nature is in distinction, for example, with those regarding utilization of G o by frizzled, wherein induction of a hypomorphic allele of G o impairs control of canonical Wnt and planar polarity pathways [50] .
Early work with vertebrate Smo, however, suggested a capacity for vertebrate Smo to engage G-proteins in at least certain circumstances. Expression of human Smo in Xenopus melanophores caused pigment aggregation [51] , an effect often associated with a reduction in cAMP and usually involving the G-protein G i . Employment of G i by Smo was substantiated in subsequent experiments in which Smo-effected aggregation was inhibited by a Bordetella pertussis toxin (PTX). PTX catalyses the ADPribosylation of most members of the G i family of G-proteins (G z is the exception, see below) at a cysteine residue near the C-terminus of respective G α subunits. This modification blocks interaction of the heterotrimeric G-protein with receptors. PTX was found, in another study [52] , to inhibit N-Shh-induced capillary morphogenesis. The toxin also elicited a phenotype in zebrafish embryos that, at least partly, mimicked that of Hh deficiency [53] . The G i family comprises three isoforms of G i (G i1 , G i2 and G i3 ), two isoforms of G o (G o1 and G o2 ), two isoforms of G t (G t1 and G t2 ) and G z . Members of the G i family are linked with reductions in cAMP through inhibition of adenylyl cyclase, but have many other actions as well.
An inhibitory effect of PTX does not actually demonstrate activation of a G i family member, nor does it provide information on G-proteins beyond the G i family. Issues of activation and selectivity were addressed in a direct assay of G-protein activation for mouse Smo and G-proteins introduced into Sf9 cells [31] . Sf9 cells provide a defined background for the expression of mammalian receptors and G-proteins introduced by means of recombinant baculovirus [54] . The assay for activation was GDP/ Vertebrate Smo therefore couples directly to members of the G i family and would seem to do so selectively. Kasai et al. [30] have reported, however, that the activation of Gli in HEK-293 cells by N-Shh is inhibited by the RGS (regulator of G-protein signalling) domain of p115 RhoGEF (guanine-nucleotide-exchange factor), which inhibits members of the G 12 family (G 12 and G 13 ). The activation of Gli in this report is also inhibited by inhibitors of the monomeric G-protein Rho, which is downstream of the G 12 family (and, in HEK-293 cells, G q as well). The requirement for the G 12 family and Rho contrasts with the negative data for G 12 and G 13 , as described above, in the direct assay of coupling using GDP/[
35 S]GTPγ S exchange. The discrepancy might be explained if the coupling of Smo to the G 12 family required a level of Smo activity beyond that achieved by the constitutive activity of Smo (the potential of Smo to activate G 12 or G 13 in direct assays was examined only for its constitutive activity); activation of G 12 or G 13 might require a greater strength of stimulus or occur as a result of an 'agonist-directed trafficking of receptor stimulus' [55] . Another possibility is that Smo interacts directly with the G i family alone, but stimulates G 12 or G 13 in HEK-293 cells indirectly through the production of autocrine factors. These possibilities are depicted in Figure 3 . Alternatively, the requirement for members of the G 12 family might be passive, i.e. this family may normally exhibit a low, but meaningful, level of basal activity that serves a permissive purpose. The top panel shows the activation of G i by Smo that, on binding of N-Shh to Ptch (Ptc), is simply unrepressed and therefore expressing a constitutive activity. The second panel entertains the hypothesis that, although N-Shh effects de-repression of Smo, it also effects production of a still to be characterized agonist that activates Smo further. The increase in stimulus strength not only causes a greater degree of G i activation, but also causes some degree of G 13 activation. The third panel entertains the notion of agonist-directed trafficking, wherein de-repressed Smo exists in a conformation that activates G i alone, whereas agonist-activated Smo is pushed into a conformation that activates (here) G 13 alone. The bottom panel illustrates the production by Smo through G i (but possibly through events at the C-terminal tail, or both, not shown) of an autocrine factor that activates another seven-pass TM receptor, which is coupled to G 13 . Variations on each of these themes exist.
A recent study reported the activation by Smo of a G q family member, G 15 , introduced into HEK-293 cells [56] . G 15 is a murine G-protein and its human counterpart is G 16 . These are commonly portrayed as promiscuous G-proteins, coupling in overexpression paradigms to a great variety of receptors that normally couple selectively to members of the G s , G i , G q or G 12 families [57] . They provide the basis for a convenient method to screen agonists [58] and, in the case of Smo, inverse agonists as well [56] . Their activation when overexpressed is not usually considered physiologically relevant without additional supporting data.
The [62] . G i and G o are present in Drosophila, so the question of coupling in this organism would seem to merit renewed interest. The G o in Drosophila appears to be a substrate for PTX, however, the G i is not, and so any work with PTX may be less than decisive.
LIMITATIONS IN DATA REGARDING G-PROTEINS
That PTX abrogates N-Shh signalling in some vertebrate cells suggests a necessity for G i . But is G i required for Hh signalling in all vertebrate cells that serve as targets? The paucity of reports regarding PTX sensitivity over a long period of time would suggest not; however, some caution should be applied to negative data. Not all cells have a mechanism for internalizing the S1 (ADPribosylating) subunit of the toxin [63] , so it is not always clear that G i is effectively ADP-ribosylated in the cell of interest. Moreover, not all members of the G i family are substrates for PTX. G z is one such protein [64] , and it is of considerable interest that G z is selectively expressed in the CNS [65, 66] , a major site of N-Shh action. Perhaps most importantly for in vivo studies, anything short of complete intoxication with PTX may not be effective [67] .
Caveats regarding PTX notwithstanding, it is possible that NShh signalling does not always require G i . Whether N-Shh depends on G i in a given cell may depend on the presence or absence of other signalling pathways, the experimental conditions and the targets being evaluated. For some cells, a requirement for G i could be pre-empted through receptor tyrosine kinases activated by serum constituents or paracrine factors that duplicate the kinds of signals G i provides.
The exact nature of the requirement for G i itself requires scrutiny. Smo activates G i , of course, but, even in cells where signalling by Smo is sensitive to PTX, is this activation strictly necessary? Some G i activity no doubt exists in an unstimulated cell, quite possibly through low-level constitutive activity of assorted G i -coupled receptors. These pre-stimulation levels of G i activity might suffice to support other forms of signalling engaged by Smo (see below), in which case an activation of G i by Smo might itself be redundant. This distinction may prove important in tests of 'sufficiency' for elements of Smo structure as they relate to G i .
It is not clear at this point what the required G i -related signals might be. Attractive candidates are the inhibition of adenylyl cyclase and the activation of Akt. PKA (cAMP-dependent protein kinase) has proven to be a strong, if not the most powerful, negative regulator of Hh signalling across animal phyla. In vertebrates, PKA-mediated phosphorylation of Gli2 and Gli3 initiates a phosphorylation cascade that leads to processing into repressors of transcription or frank degradation (see below for a detailed description). Indeed, the basal activity of PKA, possibly supported by the basal activity of adenylyl cyclases, is probably the main repressor of spontaneous (ligand-independent) signalling through the Smo pathway. Inhibition of one or more adenylyl cyclase isoforms by Smo-dependent G i activation is therefore attractive as a component of Gli activation. In Drosophila, notwithstanding, PKA also has positive effects on Hh signalling through the phosphorylation of the C-terminal tail of Smo, which is required for Smo signal transduction [68] [69] [70] . Since the PKA phosphorylation sites on the C-terminal tail of Smo are not conserved in vertebrates, it is unclear whether PKA would have similar positive effects in the context of vertebrates. In addition, G βγ subunits released from G i can activate PI3K (phosphoinositide 3-kinase), and can be therefore implicated in Smo-dependent activation of Akt [71] . Other targets for G i that merit consideration are Rac, Src and, in some tissues (heart and brain), K + channels. The latter targets have not emerged specifically in studies of Gli activation, but the link between Smo and G i will now provide the impetus to examine them more closely in this context and, additionally, in the possible signalling of Smo to effectors beyond Gli. [31] . G i is therefore not a sufficient signal in these cells. This conclusion reinforced previous work that the C-terminal tail of Smo is also an important site of signal generation [62] .
FORMS OF SIGNAL TRANSDUCTION BEYOND G-PROTEINS
The importance of the C-terminal tail is well documented for Hh signalling in Drosophila. Drosophila Smo lacking its C-terminal tail is inactive, whereas a membrane-tethered form of the Cterminal tail alone exhibits low, but significant, levels of Hhlike activity [72] . The C-terminal tail of Drosophila Smo is also extensively phosphorylated in response to Hh [49, 69] , an event required for Hh signalling. The information known for vertebrate Smo lags behind that obtained for the Drosophila protein. As described above for Drosophila Smo, the C-terminal tail of mouse Smo is required for N-Shh signalling [62] . The critical portion of the C-terminal tail is, however, near (within 90 residues) the seventh TM domain and does not correspond with the portion of the C-terminal tail required in Drosophila Smo for interaction with Cos2 (Costal 2). A chimaera containing the C-terminal tail of Drosophila Smo, but lacking the latter's Cos2 interaction sites, is a functional signalling molecule in vertebrate cells [62] . Additionally, most of the phospho-residues in Drosophila Smo are not conserved in mammalian Smo [69] , which nonetheless can be phosphorylated by GRK2 (GPCR kinase 2) [29] . The phosphorylation by GRK2 depends on the activity of Smo, which almost certainly occurs primarily, if not solely, in the C-terminal tail of Smo (by analogy to other seven-pass TM receptors), and recruits the protein β-arrestin2 to Smo, which promotes internalization of Smo. β-Arrestins are also known to promote some forms of signalling through scaffolding functions [73] . Knockdown of β-arrestin2 in zebrafish embryos leads to a lethal developmental phenotype, similar to that seen after deletion of Smo or Gli2 [74] .
The extension of GRK2's phosphorylation of Smo to functionality was performed by Meloni et al. [75] , who demonstrated a potentiation of Gli activation in C3H10T1/2 cells by the agonist SAG (Smo agonist), and by overexpressed Smo, by introduction of GRK2. Catalytically inactive GRK2 had no effect. Reduction in endogenous GRK2 with small hairpin RNA completely eliminated Gli activation by SAG through endogenous Smo. The effects of reducing endogenous β-arrestin2 by similar means were evaluated only in relation to co-transfected Smo and GRK, but were similarly deleterious to Gli activation. The signal originating with the C-terminal tail of Smo is therefore probably acting downstream of β-arrestin2.
Among proteins that interact with β-arrestins are monomeric G-proteins, MAPK (mitogen-activated protein kinase) cascade components and non-receptor tyrosine kinases [73] . None of these has come to the fore as being intimately regulated by NShh. With regard to MAPK components, signalling by N-Shh has been shown in some instances to require basal levels of MEK [MAPK/ERK (extracellular-signal-regulated kinase) kinase] 1/2 and/or ERK activity [76, 77] ; however, frank activation of ERK, where found, has been achieved through transactivation of receptor tyrosine kinases [78] . The possibility that a small subpopulation of MEK1/2 or ERK, i.e. a population that is relevant, but difficult to detect and is more immediately activated, will, however, require attention; any activation through β-arrestins may be limited by available quantities of these proteins and to the ERK retained by them in the cytosol. Smo has not yet been classified according to the stability of its interaction with β-arrestins, which influences some aspects of functionality. Nor has the possible role of G βγ in recruitment of GRK, hence β-arrestin, been evaluated.
GOING FROM Smo TO Gli
Transduction of activation of Smo in Drosophila into stabilization of Ci (Cubitus interruptus) and transcription of target genes requires the association of the cargo domain of Cos2 with the Cterminal tail of Smo, specifically with two discrete Smo domains (residues 652-686 and 730-1035) [49, 72] . Cos2 forms a so-called 'Hh signalling complex' with Fused and Ci [79] . As noted above, the signalling in vertebrates differs significantly from that in Drosophila. In vertebrates, the Cos2 orthologues KIF (kinesin family)7 and KIF27 are not required for Shh signalling [62] . Recent findings have shown that deficiency in the Fused kinase, moreover, does not elicit an Hh-like phenotype [80] .
Instead, in vertebrates, Su(Fu) (Suppressor of Fused) would appear to play a more important role in regulation. Su(Fu) is a negative regulator of Shh signalling that interacts with all three Gli proteins to retain them in the cytosol [81] . Mice deficient in Su(Fu) die at mid-gestation with ventralization of the neural tube and brain, abnormal cardiac looping and a generalized ectopic activation of Gli transcriptional targets, which is similar to ptch1 knockouts [82, 83] . Studies in isolated embryonic fibroblasts from these mice showed a high ligand-independent Gli activation, which was particularly insensitive to PKA [83] . An attractive scenario is that Su(Fu) in mammals has a scaffolding function that is required to bring together the Gli transcription factors and the negative regulator PKA, and that it is inhibited, possibly through its phosphorylation [84] , by Smo in the presence of Shh.
Levels of PKA activity achieved in the resting cell are sufficient to sustain inhibition of Gli, since introduction of a dominant-negative PKA mutant in zebrafish embryos induces ectopic expression of Gli target genes [85] . The role of PKA can in fact be dominant; even in the presence of Shh or constitutively active Smo, stimulation of PKA activity with forskolin or dibutyryl-cAMP represses Gli activation ( [86] and N. A. Riobo, unpublished work).
CONTROL OF Gli2 AND Gli3 PROCESSING AND DEGRADATION
In mammals, the role of Drosophila Ci has been assumed by three Gli proteins: Gli1, Gli2, and Gli3. The three isoforms contain five zinc-finger DNA-binding domains, but their N-terminal domains are distinct. Transcriptional reporter assays and gene expression analysis have shown that Gli1 functions as a strong transcriptional activator; its structure does not appear to encompass any repressor domain. Gli1 is required for Hh signalling in zebrafish, but targeted inactivation of gli1 in mice was fully compensated by gli2, indicating species-specific roles for Gli1. Gli1 expression is dependent on Gli2 and/or Gli3-mediated transcription, so that Gli1 expression can be used as a convenient readout of the state of pathway activation.
Generally, studies of induced expression have been the focus regarding Gli1. Degradation is, however, relevant and may be a regulated process. Huntzicker et al. [87] have found two 'degrons' (degradation sequences) in Gli1, degron N and degron C, which mediate recognition of Gli1 by the β-TrCP (β-transducin-repeatcontaining protein) E3 ubiquitin ligase, to allow ubiquitination and degradation of Gli1 by the proteasome. β-TrCP, the vertebrate homologue of Drosophila Slimb ubiquitin ligase, specifically binds phosphorylated substrates through the DpSGX 2−4 pS binding motif (where pS refers to phosphoserine and X refers to any residue). This sequence, presuming phosphorylation, is present in both degrons of Gli1. In contrast with Gli2 and Gli3 (see below), Gli1 degradation by β-TrCP appears to be complete, without generation of anything that might resemble a transcriptional repressor fragment. Degron N lies immediately adjacent to the Su(Fu)-binding site, suggesting that Su(Fu) may work in tandem with β-TrCP to facilitate cytosolic retention and efficient degradation respectively; Gli1 mutants with deletions of one or both degrons have a normal distribution, providing evidence that the degron sequences do not play a role in nucleo-cytoplasmic shuttling of Gli1. Interestingly, degron N is within a region sensitive to MEK-1, which is a positive regulator of Gli1 activity (see below). Transgenic mice overexpressing Gli1 without degron N show small basal cell carcinoma-like proliferations soon after birth, many of which form benign hair follicle tumours [87] .
Human Gli1 contains five candidate PKA phosphorylation sites (Thr 296 , Thr 374 , Ser 544 , Ser 560 and Ser 640 ), and can be phosphorylated in vitro and in vivo by PKA. The role of PKA in the regulation of Gli1 activity is not clear. As PKA influences the activities of Gli2 and Gli3 (see below), this makes investigation into the direct effect of PKA on Gli1 technically difficult to evaluate. Sheng et al. [88] reported recently that phosphorylation of Thr 374 by PKA leads to retention of Gli1 in the cytoplasm. The authors hypothesize that the close proximity of Thr 374 to the nuclear localization signal of Gli1 in the three-dimensional structure can result in a phosphorylation-dependent nuclear-cytoplasmic shuttling. In contrast, Kaesler and co-workers [89] have found that Gli1 localization is not altered by PKA activation.
Gli1 activity is exquisitely sensitive to activation and inactivation of MEK-1. The N-terminal domain (residues 1-131) of Gli1 confers the ability to be stimulated by phorbol esters, by mutationally activated MEK-1 and by growth factors that signal through the MEK pathway, such as bFGF (basic fibroblast growth factor) [77] . The mechanism by which MEK achieves regulation of Gli1 is not clear, neither is a requirement for the downstream kinases ERK1 and ERK2.
The activity of Gli1 also depends on a constitutive level of PI3K activity, which promotes stabilization of Gli2 (and possibly Gli3) by means of an Akt-dependent control of the effects of PKA [71] . However, a more direct effect of Akt on Gli1 stability has not been investigated.
Gli2 and Gli3 share a high degree of sequence similarity, including activator and repressor domains, and multiple phosphorylation sites. At least in cultured cell reporter assays, Gli2 exhibits a stronger transcriptional activity than Gli3, but a weaker activity than Gli1. A number of studies suggest that Gli2 may function exclusively as a transcriptional activator. For example, mice deficient in Gli2 show impaired Shh-dependent ventral cell type specification in the developing neural tube [90] . This phenotype can be rescued by insertion of gli1, but not gli3, into the gli2 locus [91] . Inactivation of gli2 on a gli3 null background has indicated, however, that Gli2 could have repressor activity in specific contexts as well. Analysis of the expression of different marker genes in different tissues has shown that Gli2 may act as a transcriptional activator or a repressor in zebrafish, although some of the marker genes analysed may not be direct targets of Gli2 [92] .
Gli2 is constitutively expressed, but its stability, which is intimately linked to proteasomal degradation, is tightly regulated. A determinant of the degradation rate is the extent to which Gli2 is phosphorylated. Sequence analysis shows that Gli2 contains potential and realized sites for phosphorylation by PKA (six sites), GSK-3 (glycogen synthase kinase; four sites), and CK-1 (casein kinase-1; four 'classical' sites) [71] . Some authors add several non-optimal CK-1 sites, elevating the total number of potential phospho-residues to 22. Typically, activation of PKA leads to phosphorylation of at least three clustered PKA sites, which generates recognition sites for GSK-3 and CK-1 by a process referred to as 'priming'. Gli2 can also be phosphorylated directly by CK-1 at the non-optimal sites, albeit to a lower extent, in the absence of priming. The phosphorylated Gli2 protein interacts with β-TrCP, and is ubiquitinated and degraded by the proteasome [93] .
Frank degradation notwithstanding, evidence is emerging that Gli2 can also be proteolytically processed to yield a repressor. With the use of a protocol designed to detect small amounts of Gli2 cleavage, Pan et al. [93] reported that around one-sixth to one-tenth of total Gli2 is proteolytically processed to generate Gli2-R (a 78 kDa transcriptional repressor fragment of Gli2) by in vivo and in vitro assays. Gli2 would therefore appear to be proteolytically processed for inhibitory purposes, but inefficiently. The low amount of Gli2-R in comparison with the full-length Gli2 probably masked the appreciation of a processing mechanism for Gli2. Both Gli2 processing and frank degradation are inhibited by Shh signalling in vivo.
The activation (stabilization) of Gli2 by Shh can be achieved through several mechanisms. The first is the inhibition of phosphorylation. It seems logical to presume that PKA is inhibited by Shh, and it is tempting to propose that inhibition of PKA is caused by a reduction in resting levels of cAMP. Two reports support a reduction of cAMP [51, 94] , however, another does not [40] . The former studies show a rapid decrease in cAMP in retinal ganglion cells upon exposure to Shh [94] and an increase in pigment aggregation, which is associated with constitutive G i protein activation, in frog melanophores [51] . The third study found no effect of Shh on forskolin-stimulated cAMP production in C3H10T1/2 cells [40] . It is noteworthy that all membrane-bound adenylyl cyclase isoforms are activated by forskolin, but not all are sensitive to inhibition by G i proteins [95] . A second mode of stabilization of Gli2 by Shh signalling is the activation of PI3K and Akt by a Smo-dependent mechanism. We have shown that Akt is required to counteract the negative regulation of Gli2 by PKA, since the activity of a Gli2 variant with the four clustered PKA phosphorylation sites mutated to alanine is completely resistant to inhibition of PI3K or Akt activities [71] . Moreover, this mutant is substantially more stable in HEK-293 and NIH 3T3 cells than wild-type Gli2 in the presence of a dominant-negative Akt. Another predicted action of PI3K and Akt activation is to inhibit GSK-3 through phosphorylation. Some signalling events engaged by Shh therefore contribute to reduce the activity of two of the kinases that phosphorylate Gli1, Gli2 and Gli3, by promoting their stability and reducing their processing into repressors.
Gli2 and Gli3 share an overall amino acid identity of 44 %, including the conserved PKA sites. In contrast with the gli1 results, loss-of-function mutations in gli3 result in phenotypes that largely resemble those produced by activation of Hh signalling in both mice and humans [96, 97] . Gli3, therefore, mainly functions as a transcriptional repressor that is suppressed through Hh signalling. The full-length 190 kDa Gli3 protein is efficiently processed in the absence of Hh to generate Gli3-R (an 83 kDa transcriptional repressor fragment of Gli3) [98] . Gli3-R localizes to the cell nucleus where it binds Gli-responsive elements to prevent ectopic induction. Extension of mechanistic studies from Ci to Gli3 were instrumental in the identification of phosphorylation sites for PKA, GSK-3 and CK-1, which are conserved between the two proteins. The PKA-dependent processing of Gli3 in the developing mouse limb is antagonized by long-range posterior Shh signalling [98] . As a result, Gli3 forms an anteriorposterior repressor gradient. Mutations of Gli3 in humans, or mis-regulation of Gli3 processing in the chicken mutant talpid2, produce a range of limb patterning malformations. GCPS (Greig cephalopolysyndactyly syndrome) is a rare autosomal dominant developmental disorder characterized by craniofacial abnormalities and post-axial and pre-axial polydactyly, as well as syndactyly of hands and feet. Most individuals with GCPS have point mutations in the gli3 gene [99] . Among the best characterized, a nonsense mutation in exon 10 generates a stop codon right before the first zinc finger. In another case, a missense mutation in exon 14 causes a proline to serine residue replacement at a position that is conserved among Gli genes from several species, altering a potential phosphorylation site, and therefore the control of Gli3 processing.
Gli3, like Gli1 and Gli2, is subject to the actions of β-TrCP. Phosphorylated Gli3 can bind β-TrCP directly both in vitro and in vivo, resulting in polyubiquitination of Gli3 and processing through proteasome activity [100, 101] . In principle, PKA, CK-1 and GSK3 can phosphorylate as many as 19 serine residues in Gli3: four PKA sites, three primary GSK3 sites, four primary CK-1 sites and eight secondary GSK3 and CK-1 sites. It is interesting that, as most substrates of β-TrCP undergo complete degradation after multiple-site ubiquitination, complete degradation of Gli3 is not dominant. Another example is the processing of NF-κB (nuclear factor κB)/p105 to form the functional NF-κB/p50. A common feature between Gli3 and NF-κB/p105 is that their C-terminal fragments seem to be totally degraded by the proteasome. Processing of both NF-κB/p105 and Gli3 requires phosphorylation at their C-terminal domains, which probably promotes the binding of β-TrCP. They differ, however, in that Gli3 is phosphorylated at numerous sites by at least three kinases, whereas NF-κB/p105 is phosphorylated at fewer sites by IκB (inhibitory κB) kinase [102] . There is some room to speculate that Gli3 may be cleaved by a site-specific protease and that proteasome function is merely required to degrade the polyubiquitinated Gli3 C-terminal fragment after it is cleaved. If the latter were the case, it would not be expected that proteasome inhibitors would block Gli3 processing, unless processing and degradation are tightly coupled processes. Deletion of the normal cleavage site in Gli3 does not affect the efficiency of its processing, suggesting that a site-specific protease is not involved in the generation of the Gli3-R fragment.
Regulation of Gli3 phosphorylation and processing is likely to depend on the same mechanisms as those relevant to Gli2. Parallel activation of PI3K and Akt, and reduction of PKA and GSK-3 enzymatic activities, would certainly be reflected in an improved stability of full-length Gli3 (the weak transcriptional activator form) and a reduced rate of formation of the Gli3-R.
ADDITIONAL REGULATORS OF Gli TRANSCRIPTIONAL CAPACITY
In recent years, a number of additional levels of regulation of the mammalian Hh pathway have been reported. Hh signalling does not engage these pathways, and therefore they are not considered part of the central Hh transduction pathway.
The dual specificity Dyrk1 (Yak1-related kinase type 1) is a nuclear-localized protein kinase distantly related to MAPKs and cyclin-dependent kinases. Co-expression of Gli1 and Dyrk1, but not a kinase-dead Dyrk1 mutant, increases localization of Gli1 to the nucleus. Dyrk1 phosphorylates Gli1 on more than one domain [103] . Dyrk1 acts synergistically with Shh to induce transcription of a Gli-promoter-driven luciferase reporter gene and of endogenous alkaline phosphatase in mouse C3H10T1/2 cells. Addition of Shh does not stimulate Dyrk1 kinase activity. Instead, Dyrk1 is activated by tyrosine autophosphorylation while it is being synthesized on the ribosomes [104] .
Several prostate cancer cell lines depend on Shh for survival and proliferation. Mimeault et al. [105] have reported that for LNCaP, DU145 and PC3 cells, which are established cellular models of prostate cancer, inhibition of Smo with cyclopamine and of the EGFR (epidermal growth factor receptor) with genetifib (Iressa) has synergistic antiproliferative and cytotoxic effects. Apoptosis induced by these drugs in PC3 cells appears to be mediated by the mitochondrial pathway through the depolarization of the mitochondrial membrane, cytosolic release of cytochrome c and production of reactive oxygen species. In addition, the combined cyclopamine and gefitinib treatment was more effective at suppressing the invasiveness of PC3 cells through Matrigel TM . This result suggests that the EGFR signalling pathway may interact with the Hh pathway.
Another protein that potentiates Gli transcriptional activity is MIM (missing in metastasis), an Shh-target gene that is enriched in basal cell carcinomas [106] . MIM is known for its role in regulation of the actin cytoskeleton by virtue of binding monomeric actin and bundling F-actin [107] . MIM has been described to interact through independent domains with Gli1, Gli2 and Su(Fu) to form a complex. It is not clear how these interactions promote Gli-mediated transcriptional activity, but one possibility is that MIM prevents Su(Fu) inhibitory actions on Gli. Another is that MIM, through an interaction with Rac [108] , activates a localized MAPK cascade, which potentiates Gli1 and Gli2 activities [77] .
An intriguing protein that potentiates vertebrate Hh signalling is megalin (or LPR-2), which belongs to the LDL (low-density lipoprotein)-receptor-related family. Megalin binds N-Shh with high affinity and promotes its endocytosis, a process that can be inhibited by heparin [109] . Megalin is a multi-ligand receptor involved in endocytosis of protein ligands and lipid-binding proteins, including, perhaps not surprisingly, vitamin D 3 (for a comprehensive list of substrates see [110] ). The endocytic role of megalin may suggest a negative effect on Hh signalling, but a positive role in trafficking has been proposed [111] .
Dzip1 is a single zinc-finger protein that promotes nuclear localization of Gli1 in zebrafish and which functions as a permissive factor for regulation of Hh target genes in response to Hh signalling [112, 113] . Dzip1 may act directly in nuclear import, or in the sequestration of factors that retain Gli in the cytoplasm.
An exciting role for IFTs (intraflagellar transport proteins) in co-ordinating diverse signalling pathways in vertebrate cells [114] has been documented recently to be essential for Shh [115] . IFTs regulate the proper localization of Smo, Su(Fu) and Gli proteins in the primary cilia [115] [116] [117] [118] , and they regulate both activator and repressor functions of Gli2 and Gli3. The groups of Anderson and Reiter have pioneered the concept that the primary cilium in vertebrates may act as a signalosome that brings together the core components of the Hh pathway, perhaps in much the same way as Cos2 in Drosophila [116, 119] . This would constitute a major point of divergence of vertebrate and invertebrate systems. A review emphasizing the role of ciliary proteins in Shh signal transduction has been published recently [27] .
A number of additional negative regulatory factors have emerged in vertebrate Hh signalling. FKBP8 (FK506 binding protein 8) is a transcription factor whose loss causes ectopic and ligand-independent activation of the Hh pathway solely in the nervous system, despite being broadly expressed, suggesting a cell-type specific modulation of Hh signalling during mammalian development [120] . A similar action was proposed for Rab23, a small GTPase that regulates vesicular trafficking. Rab23-deficient mice display a ventralized neural tube and an open brain phenotype [121] . Double mutant analysis demonstrated that Rab23 does not work through Ptch1 or Smo. Instead, the primary action of Rab23 appears to be the facilitation of Gli2 and Gli3 processing into transcriptional repressors by regulating the localization of components that act downstream of Smo and upstream of the Gli proteins [121] .
TRANSCRIPTIONAL INDEPENDENT ACTIONS OF Hh PROTEINS
Although the actions of Hh ligands attracting the most attention are those effected through induction of Gli, there are a few reports of responses to Hh that do not seem to involve de novo transcription. One of these is changes in cell motility and morphology, more often than not involving increased migration [122, 123] and also additional forms of chemoattraction [124, 125] . In vivo models of spinal cord commissural axon growth in mice and in spinal cord explants, Shh produced in the notochord is required, in collaboration with netrin-1, to induce proper axon outgrowth [124] . Purified N-Shh can directly elicit axon extension in isolated spinal neurons in culture within 1 h, and this chemoattractant effect can be effectively blocked by cyclopamine [124] . Similarly, chick retinal ganglion cells respond to low concentrations of N-Shh (0.5 µg/ml) with increased axonal growth in less than 30 min, again suggesting a non-transcriptional mechanism [125] . A higher concentration of N-Shh (2.5 µg/ml) induces rapid (< 15 min) cone retraction in the same model and a rounding up of dendrites [94, 125] . Rounding up is a common outcome of G 12 -dependent processes, through activation of Rho and ROCK (Rho-activated kinase), and formation of stress fibres [126] . As discussed above, we do not rule out activation of G 12 proteins at high ligand concentrations or, indirectly, through rapid secretion of agonists that signal through G 12 . Trousse et al. [94] also report a decrease in intracellular cAMP levels in chick retinal ganglion cells, as determined after 20 min stimulation with NShh by immunofluorescence using anti-cAMP antibodies, which was consistent with effective activation of G i through Smo [31] . Cues for axon guidance trigger a cascade of cytoplasmic events that usually converge on cAMP. Thus increased levels of cAMP in neurons induce cone extension, whereas low levels of cAMP are associated with the inhibition and retraction of the growth cone movements [127] .
In explants of mouse neural tube, normal dispersion of neural crest cells is prevented by addition of N-Shh to the culture medium [128] . The mechanism appears to involve reduced cell spreading and induction of compaction. The authors claim that the activity of Shh on cell migration is dependent on the first 10-15 amino acids of N-Shh. They found, using different N-Shh mutants and blocking antibodies, that the most N-terminal region of N-Shh, although not required for binding to Ptch, is required for inhibition of neural crest cell dispersion. Cyclopamine cannot prevent this effect of N-Shh; moreover, leading to the interesting possibility that some signals triggered by Shh can be not only Gli-independent, but also Smo-and Ptch1-independent.
CONCLUDING REMARKS
The complexity of Hh signalling in vertebrates is daunting (Figure 4) ; however, the importance of this signalling in developmental and post-embryonic homoeostatic events has provided con- siderable incentive to understand each facet of Hh signalling completely. Key mechanistic questions are currently those of Hh presentation and transduction. As more information is gained, the extent to which Hh signalling involves conceptually unique elements will become clearer. Concepts of de-repression, exemplified by Hh relief of an inhibitory constraint on a seven-pass TM protein, have few parallels, yet the relevance of G-proteins and GRK/arrestin points to elements held in common with other systems. There is no doubt that Hh signalling is subject to many forms of superimposed regulation that will probably shape responses to fit the function of the target cell. Although regulation of the Gli transcription factors is a primary action of the Hh proteins, and one that has substantial impact, it is clear that the Hh proteins can achieve some actions apart from, and of a more immediate nature than, transcription in general.
